Ono Pharmaceutical (OTCMKTS:OPHLF) Share Price Passes Above 50 Day Moving Average - Here's Why

Key Points

• Ono Pharmaceutical's stock has recently moved above its 50-day moving average of $11.48, trading as high as $11.68, but closed at $10.27 with a volume of 1,000 shares.
• The company reported earnings per share (EPS) of $0.26 for the last quarter, falling short of analyst expectations of $0.34, despite exceeding revenue forecasts of $827.29 million with actual revenue of $886.27 million.
• Ono Pharmaceutical holds a market capitalization of $4.82 billion, along with a low debt-to-equity ratio of 0.13 and a P/E ratio of 16.56.

Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report)'s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $11.48 and traded as high as $11.68. Ono Pharmaceutical shares last traded at $10.27, with a volume of 1,000 shares.

Ono Pharmaceutical Stock Performance

The company has a quick ratio of 2.44, a current ratio of 2.99 and a debt-to-equity ratio of 0.13. The firm's 50 day moving average is $11.46 and its two-hundred day moving average is $11.03. The stock has a market cap of $4.82 billion, a price-to-earnings ratio of 16.56 and a beta of 0.19.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.34 by ($0.08). Ono Pharmaceutical had a return on equity of 5.47% and a net margin of 8.75%.The business had revenue of $886.27 million for the quarter, compared to analyst estimates of $827.29 million.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.